Senzar Asset Management adds Amgen (AMGN) to its portfolio

Amgen (AMGN) : Senzar Asset Management added new position in Amgen during the most recent quarter end. The investment management firm now holds 269,300 shares of Amgen which is valued at $41 Million , the company said in a statement filed on May 13, 2016 with the SEC.Amgen makes up approximately 8.03% of Senzar Asset Management’s portfolio.

Other Hedge Funds, Including , Rotella Capital Management sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 2,800 shares of AMGN which is valued $426,580.Amalgamated Bank boosted its stake in AMGN in the latest quarter, The investment management firm added 7,177 additional shares and now holds a total of 30,160 shares of Amgen which is valued at $4.6 Million. Amgen makes up approx 0.45% of Amalgamated Bank’s portfolio.Tradewinds Capital Management boosted its stake in AMGN in the latest quarter, The investment management firm added 1 additional shares and now holds a total of 6,717 shares of Amgen which is valued at $1 Million. Amgen makes up approx 0.71% of Tradewinds Capital Management’s portfolio.Rockefeller Financial Services Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 1,628 additional shares and now holds a total of 5,189 shares of Amgen which is valued at $821,419. Amgen makes up approx 0.02% of Rockefeller Financial Services Inc’s portfolio.Whittier Trust Co boosted its stake in AMGN in the latest quarter, The investment management firm added 612 additional shares and now holds a total of 60,453 shares of Amgen which is valued at $9.6 Million. Amgen makes up approx 0.42% of Whittier Trust Co’s portfolio.

Amgen opened for trading at $153.54 and hit $155.84 on the upside on Wednesday, eventually ending the session at $155.57, with a gain of 1.87% or 2.85 points. The heightened volatility saw the trading volume jump to 30,53,390 shares. Company has a market cap of $116,867 M.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Citigroup Initiated Amgen on Feb 25, 2016 to “Neutral”, Price Target of the shares are set at $165.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.